Sunny Pharmtech benefited last year from obtaining two U.S. drug certifications for its anticancer injection (CPA-I) and anticoagulant (AMA-S), with operating losses of NT$72.1 million, post-tax losses of NT$63.32 million, and a loss per share of NT$0.44, all significantly converging from the previous year's losses.
With operations gradually improving, Sunny Pharmtech experienced simultaneous growth in drug sales and profit sharing, project milestone payments, and CDMO (Contract Development and Manufacturing Organization) services, driving its consolidated revenue to reach NT$428 million last year, reaching a historic high and representing a 19.2% year-on-year increase. Additionally, with the increase in the proportion of high-margin milestone payments, the gross profit margin rose to 66%, up from 58% in the previous year, expanding by more than eight percentage points. Coupled with prudent cost control, this significantly improved the annual loss.
Sunny Pharmtech stated that with the recovery of drug sales, the addition of joint development projects and CDMO agreements, as well as contributions from milestone achievements in the development of new drugs, the company's operations significantly improved in the first half of last year. In the second half of the year, it obtained the U.S. drug certifications for CPA-I and AMA-S, leading to better revenue and profit performance compared to the first half of the year, further reducing losses.
Sunny Pharmtech pointed out that the recently launched CPA-I, which treats multiple cancers, generated approximately USD 100 million in sales in the United States in the past year. Due to the absence of sales of original drugs in the market and limited competition, the product is currently being shipped in large quantities, presenting an opportunity to capture a certain market share. As for the AMA-S, which adopts a suspension formulation, obtaining certification will strengthen the existing portfolio of tablet anticoagulant products, leading to synergistic sales effects. The company is currently actively preparing for market launch.
In terms of drug certification layout, the company currently has three, one, and one items undergoing certification review in the United States, China, and Taiwan, respectively. It will also accelerate its "one drug, multiple certifications" strategy to expand into markets outside the United States, aiming to maximize product value. In addition to planning to submit certification applications for two items in the United States this year, it will also submit applications for one item each in China, Mexico, the United Kingdom, and Saudi Arabia.
Cumulative consolidated revenue for the first two months of this year reached NT$88.83 million, a 56% year-on-year increase, mainly due to growth in sales of various drug products. With visibility of orders extending to June based on current production schedules, and the opportunity to obtain additional U.S. certifications and expand into markets outside the United States this year, Sunny Pharmtech is optimistic about its full-year operational outlook and expects to achieve new highs in performance.
